Astellas submitted test data on Flomax to U.S. FDA

TOKYO, July 1 (Reuters) - Astellas Pharma Inc (4503.T), Japan's second-largest drugmaker, said on Wednesday it has submitted test data on its No.2 drug Flomax to the U.S. Food and Drug Administration.

If the data meets FDA requirements, Astellas will be able to extend its exclusive sales rights on Flomax, a drug for prostate problems, in the U.S. until April next year. Astellas is scheduled to lose U.S. patent protection in October. (Reporting by Mayumi Negishi)